The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
Open accessAbstract
On September 2, 2017, the U.S. Food and Drug Administration approved gemtuzumab ozogamicin (GO; Mylotarg; Pfizer, New York City, NY) for treatment of relapsed or refractory (R/R) CD33-positive acute myeloid leukemia (AML) in patients 2 years of age and older. GO is a CD33-directed antibody drug conjugate linked to the cytotoxic antibiotic calicheamicin. It originally received accelerated approval for treatment of older patients with relapsed CD33-positive AML in 2000, but it was withdrawn from the market in 2010 when the confirmatory trial failed to demonstrate clinical benefit among safety concerns, such as a higher rate of induction fatalities on the GO combination arm compared with chemotherapy alone. In addition, GO was associated with hepatic veno-occlusive disease (VOD), which has substantial morbidity and mortality. Pharmacokinetic analyses suggested a lower maximum concentration of GO would result in less VOD without affecting target saturation or efficacy. A meta-analysis across dose schedules of GO in patients with R/R AML showed that a lower-dose “fractionated” schedule of 3 mg/m2 days 1, 4, and 7 was associated with less early mortality, hemorrhage, and VOD, without an apparent decrease in complete remission (CR) rate. MyloFrance 1 was a single-arm study evaluating response rates in patients with relapsed CD33-positive AML treated with the lower-dose fractionated GO regimen. The CR rate was 26% (95% confidence interval 16%–40%). Common adverse reactions were fever, infections, nausea, vomiting, constipation, bleeding, increased liver enzymes, and mucositis. There were no cases of VOD. These results supported the approval of GO as monotherapy for R/R CD33-positive AML using the lower-dose fractionated regimen. Implications for Practice: Gemtuzumab ozogamicin (GO) 3 mg/m2 days 1, 4, and 7 is an active regimen for induction of remission when used to treat patients with relapsed or refractory CD33-positive acute myeloid leukemia without curative intent. The risks of hepatic veno-occlusive disease and early mortality with this regimen appear to be lower than reported previously for GO 9 mg/m2 days 1 and 15. The data were not sufficient to enable conclusions about the safety of GO in children younger than 2 years of age.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Castaigne, S., Pautas, C., Terré, C., Raffoux, E., Bordessoule, D., Bastie, J.-N., Legrand, O., Thomas, X., Turlure, P., Reman, O., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60485-1 · Cited by 1,015
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross, P. F., Beitz, J. G., Chen, G., Chen, X., Duffy, E. J., Kieffer, L. V., Roy, S., Sridhara, R. N., Rahman, A., Williams, G., et al. (2001) · PubMed · Cited by 855
Self-citationPetersdorf, S. H., Kopecky, K. J., Slovak, M., Willman, C., Nevill, T., Brandwein, J., Larson, R. A., Erba, H. P., Stiff, P. J., Stuart, R. K., et al. (2013) · Blood · doi:10.1182/blood-2013-01-466706 · Cited by 638
Prognostic Index for Adult Patients With Acute Myeloid Leukemia in First Relapse
Breems, D. A., Van Putten, W. L. J., Huijgens, P. C., Ossenkoppele, G. J., Verhoef, G. E. G., Verdonck, L. F., Vellenga, E., De Greef, G. E., Jacky, E., Van der Lelie, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.027 · Cited by 511
Amadori, S., Suciu, S., Selleslag, D., Aversa, F., Gaidano, G., Musso, M., Annino, L., Venditti, A., Voso, M. T., Mazzone, C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0060 · Cited by 362
How I treat refractory and early relapsed acute myeloid leukemia
Thol, F., Schlenk, R. F., Heuser, M., & Ganser, A. (2015) · Blood · doi:10.1182/blood-2014-10-551911 · Cited by 303
Chen, X., Xie, H., Wood, B. L., Walter, R. B., Pagel, J. M., Becker, P. S., Sandhu, V. K., Abkowitz, J. L., Appelbaum, F. R., & Estey, E. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3518 · Cited by 257
Expression of normal myeloid-associated antigens by acute leukemia cells
Dinndorf, P., Andrews, R., Benjamin, D., Ridgway, D., Wolff, L., & Bernstein, I. (1986) · Blood · doi:10.1182/blood.v67.4.1048.1048 · Cited by 229
Jen, E. Y., Ko, C.-W., Lee, J. E., Del Valle, P. L., Aydanian, A., Jewell, C., Norsworthy, K. J., Przepiorka, D., Nie, L., Liu, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3179 · Cited by 208
Self-citationRoboz, G. J., Rosenblat, T., Arellano, M., Gobbi, M., Altman, J. K., Montesinos, P., O'Connell, C., Solomon, S. R., Pigneux, A., Vey, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.8562 · Cited by 198
Pollard, J. A., Loken, M. R., Gerbing, R. B., Raimondi, S. C., Hirsch, B. A., Aplenc, R., Bernstein, I. D., Gamis, A. S., Alonzo, T. A., & Meshinchi, S. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.6846 · Cited by 147
Zwaan, C. M. (2003) · Blood · doi:10.1182/blood-2002-07-1947 · Cited by 101
Zwaan, C. M., Reinhardt, D., Zimmerman, M., Hasle, H., Starý, J., Stark, B., Dworzak, M. N., Creutzig, U., Kaspers, G. J. L., & on behalf of the International BFM Study Group on Paediatric AML (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.08011.x · Cited by 91
Gemtuzumab Ozogamicin for Relapsed and Refractory Acute Myeloid Leukemia and Myeloid Sarcomas
Piccaluga, P. P., Martinelli, G., Rondoni, M., Malagola, M., Gaitani, S., Isidori, A., Bonini, A., Gugliotta, L., Luppi, M., Morselli, M., et al. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819042000219485 · Cited by 71
Azacitidine for the treatment of relapsed and refractory AML in older patients
Itzykson, R., Thépot, S., Berthon, C., Delaunay, J., Bouscary, D., Cluzeau, T., Turlure, P., Prébet, T., Dartigeas, C., Marolleau, J., et al. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.11.009 · Cited by 70
Outcome of older patients with acute myeloid leukemia in first relapse
Sarkozy, C., Gardin, C., Gachard, N., Merabet, F., Turlure, P., Malfuson, J., Pautas, C., Micol, J., Thomas, X., Quesnel, B., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23498 · Cited by 50
Lessons Learned: Dose Selection of Small Molecule–Targeted Oncology Drugs
Bullock, J. M., Rahman, A., & Liu, Q. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2646 · Cited by 50
Tallman, M. S., McDonald, G. B., DeLeve, L. D., Baer, M. R., Cook, M. N., Graepel, G. J., & Kollmer, C. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1275-2 · Cited by 42
Cited by
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Fu, Z., Li, S., Han, S., Shi, C., & Zhang, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00947-7 · Cited by 1,643
Antibody–drug conjugates for cancer
Chau, C. H., Steeg, P. S., & Figg, W. D. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31774-x · Cited by 816
Exploring the next generation of antibody–drug conjugates
Tsuchikama, K., Anami, Y., Ha, S. Y. Y., & Yamazaki, C. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00850-2 · Cited by 659
Antibody-Drug Conjugate-Based Therapeutics: State of the Science
Birrer, M. J., Moore, K. N., Betella, I., & Bates, R. C. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz035 · Cited by 439
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023) · Cancers · doi:10.3390/cancers15030713 · Cited by 441
Metadata
- Authors
- Norsworthy, K. J., Ko, C.-W., Lee, J. E., Liu, J., John, C. S., Przepiorka, D., Farrell, A. T., & Pazdur, R.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-04-12
- Volume
- 23
- Issue
- 9
- Pages
- 1103-1108
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2798249412
- Cited by
- 269
- References
- 18
- FWCI
- 12.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.